Sign in Subscribe
Cancer research

RNA Editing Gene APOBEC3C Identifies As Candidate Tumor Suppressor in Prostate Cancer

Strategic Insights

— 1 min read

Fresh data on prostate cancer research reveal that the RNA editing gene APOBEC3C has been identified as a potential candidate tumor suppressor. According to a study published in the journal Scientific Reports, the researchers investigated the role of APOBEC3C in prostate cancer (PCa) and found that it exhibits significant positive correlations in both primary PCa and castration-resistant prostate cancer (CRPC). The study's results suggest that APOBEC3C expression inversely correlates with PCa relapse and mortality, and low APOBEC3C levels are linked to unfavorable survival.

Key Takeaways:

  • The RNA editing gene APOBEC3C is identified as a potential candidate tumor suppressor in prostate cancer.
  • APOBEC3C expression is significantly positively correlated with both primary PCa and CRPC.
  • APOBEC3C expression inversely correlates with PCa relapse and mortality.
  • Low APOBEC3C levels are linked to unfavorable survival.
  • The study provides a foundation for further RNA editors research in PCa diagnosis and therapy.
  • APOBEC3C had the best diagnostic performance among 19 genes studied.
  • Integrated analyses identified APOBEC3C as the sole RNA-editing gene with significance in both differential expression and PCa prognosis.
  • The research was financially supported by multiple institutions, including the Natural Science Basic Research Program of Shaanxi Province and the National Natural Science Foundation of China.

Statistics:

  • 19 genes were studied in the research, with APOBEC3C showing the best diagnostic performance.
  • The study analyzed PCa samples from various stages, including grade IV/V, stage III-IV, and pathological stage T3-4.
  • The results showed a significant inverse correlation between APOBEC3C expression and PCa relapse and mortality.
  • The study's integrated analyses identified APOBEC3C as the sole RNA-editing gene with significance in both differential expression and PCa prognosis.

Sources:

  • Characterization of RNA editing gene APOBEC3C as a candidate tumor suppressor in prostate cancer. Scientific Reports, 2025,15(1):1-16.
  • (Scientific Reports - http://www.nature.com/srep/index.html).
  • Natural Science Basic Research Program of Shaanxi Province.
  • National Natural Science Foundation of China.
  • Huangshi Innovation Joint Development Fund.
  • Wuhan Knowledge Innovation Project For Basic Research.
  • University-industry Collaborative Education Program.
  • Hubei Natural Science Foundation.

Read more